Incyte Corp.s (INCY) Jakafi, proposed for the additional indication as a treatment for adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease, awaits the FDA decision on September 22.Jakafi is already approved in the U.S. for intermediate or high-risk myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and for steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.Jakafi is marketed by Incyte in the U.S. and by Novartis as Jakavi outside the U.S.The drug generated annual sales of $1.94 billion for Incyte in 2020, up 15% over 2019.For 2021, Incyte has forecast Jakafi sales to be in the range of $2.125 to $2.20 billion.INCY closed Friday’s trading at $75.68, up 0.71%.